Search

Your search keyword '"Gleave, Martin E."' showing total 1,600 results

Search Constraints

Start Over You searched for: Author "Gleave, Martin E." Remove constraint Author: "Gleave, Martin E."
1,600 results on '"Gleave, Martin E."'

Search Results

3. High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker

4. Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance

5. Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.

6. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort

7. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

8. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

9. Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer

11. Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study.

12. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.

13. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

14. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer

15. Reply by Author

16. Long Term Second Malignancies in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy and Radical Prostatectomy

17. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)

18. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity

19. Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer

20. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes

21. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study

22. Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer

23. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

24. A novel type-2 innate lymphoid cell-based immunotherapy for cancer

26. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.

27. Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study

28. Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.

29. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.

30. Prostate Cancer Risk Stratification by Digital Histopathology and Deep Learning.

32. LIN28B promotes the development of neuroendocrine prostate cancer

33. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives

34. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

35. MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.

37. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells

38. Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary–Early Detection Research Network Active Surveillance Biopsy Risk Calculator

39. Functional mapping of androgen receptor enhancer activity

41. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

45. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

46. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

48. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.

49. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial

50. Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

Catalog

Books, media, physical & digital resources